Adagene Inc. (NASDAQ:ADAG)
| Market Cap | $66.26M-2.2% |
| Revenue (ttm) | $9.32M+1054.7% |
| Net Income | -$20.56M-85.2% |
| EPS | -$0.47-71.1% |
| Shares Out | 37.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,371,420 |
| Open | $2.00 |
| Previous Close | $2.01 |
| Day's Range | $1.35 - $2.05 |
| 52-Week Range | $1.27 - $4.85 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | $8.25(+368.75%) |
| Earnings Date | Mar 31, 2027 |
About ADAG
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Adagene Inc. Stock Analysis — InsiderScore
Adagene Inc. scored higher than 45% of companies evaluated by InsiderBuying, and ranked 46th out of 107 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Adagene Inc. bought $70.0K of stock across 2 purchases in the last 90 days, the largest of them $64.0K.
The average purchase added about 24% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating ADAG in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 31, 2027Earnings report
$ADAG stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADAG holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADAG's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADAG Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADAG patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADAG from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ADAG
| PGJInvesco Golden Dragon China ETF | $103.26K |
| EWXState Street SPDR S&P Emerging Markets Small Cap ETF | $55.07K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ADAG’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical milestones including Phase 1 dosing initiation, Phase 2 enrollment completion, and new trial launch demonstrate pipeline progress and advancement.
Recent Insider Activity
Insider Score Trend Over Time
-13.2 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PGJ | Invesco Golden Dragon China ETF | 0.14% |
Weight is the stock’s share of each fund’s holdings.
